McKesson CorporationNYSE: MCK
Health Care · Health Care Distributors
$750.08
-3.81%
Vol: 1.2M
Research Digest
Friday, June 19, 2026
No significant overnight updates
No material news in the last 48 hours.
Previous Market Intelligence
13 daysJun 18No significant overnight updatesNeutral▶
No material news in the last 48 hours.
Jun 17No significant overnight updatesNeutral▶
No material news in the last 48 hours.
Jun 16No significant overnight updatesNeutral▶
No material news in the last 48 hours.
Jun 15No significant overnight updatesNeutral▶
No material news in the last 48 hours.
Jun 14No significant overnight updatesNeutral▶
No material news in the last 48 hours.
May 21McKesson reaffirms long-term growth targets with new CFO Kenny Cheung joining May 29 as Citi lowers PT to $945Mixed▶
McKesson is preparing for a major CFO transition with Kenny Cheung set to join as Executive Vice President and CFO effective May 29, succeeding retiring CFO Britt Vitalone. On May 15, an analyst reiterated a Buy rating citing durable growth and biosimilar tailwinds. Citi lowered its price target to $945 from $975 on May 14, while Wells Fargo reaffirmed Hold on May 13. The company recently posted strong FY2026 Q4 results with consolidated revenues of $96.3B (up 6%) and adjusted EPS of $11.69 (up 16%), and authorized an additional $5B share repurchase bringing total authorized to $7.7B. Effective May 1, Brian Tyler was elected Chair of the Board and Dominic J. Caruso became Lead Independent Director. The Apollo $1.25B convertible preferred investment for 13% of the Medical-Surgical Solutions segment is advancing.
May 20McKesson posted FY26 Q4 results with $96.3B in quarterly revenue (+6%) on May 7, then drew a target cut from Citi to $945 and a raise from UBS to $1,050 in mid-May.Mixed▶
McKesson reported FY26 Q4 results on May 7 with quarterly revenue of $96.3B (+6%), adjusted EPS of $11.69 (+16%), and full-year adjusted EPS of $39.11 (+18%) above long-range targets. The company entered a $2.25B accelerated share repurchase program and the board authorized an additional $5.0B, bringing total authorized to $7.7B. Brian Tyler was elected Chair effective May 1, and incoming CFO Kenny Cheung takes over May 29. The Apollo Funds deal for a 13% minority interest in Medical-Surgical Solutions (valuing MMS at $13B) progressed. Citi cut its price target to $945 from $975 while UBS raised theirs to $1,050 from $1,000. Shares were $774.47 on May 18.
May 19Citi cut McKesson's price target to $945 from $975 (Buy maintained) following fiscal Q4 results showing $96.3B in revenue (+6%) and $11.69 adjusted EPS, with CFO Kenny Cheung set to start May 29.Mixed▶
Citi lowered its McKesson price target to $945 from $975 while maintaining a Buy rating, after the May 7 fiscal Q4 2026 print delivered $96.3B in revenue, up 6%, and adjusted EPS of $11.69, up 16% and roughly 1% above consensus. McKesson approved an additional $5.0B share repurchase authorization (bringing total authorization to $7.7B) and entered a $2.25B accelerated share-repurchase program, an aggressive capital-return signal. Effective May 1, Brian Tyler was elected Board Chair and Dominic Caruso became Lead Independent Director, and Kenny Cheung joins as EVP and CFO on May 29, succeeding Britt Vitalone. The previously announced Apollo deal for a ~13% minority stake in Medical-Surgical Solutions remains pending regulatory approval. Why it matters: the larger buyback and reaffirmed long-term growth targets underline confidence in earnings power and capital allocation. The bear case: revenue missed Citi's bar enough to warrant a $30 target cut, leadership turnover in the CFO seat introduces execution risk, and biosimilar/Med-Surg separation timing remains a swing factor.
May 18McKesson posted Q1 CY2026 (fiscal Q4) revenue of $96.3B (+6% YoY, but 5.3% revenue miss) and $11.69 adj EPS (+16% YoY, 1.1% beat); Citi cut its PT to $945 (from $975) on May 14 while UBS raised to $1,050 (from $1,000) on May 8 and a $5B share buyback was authorized.Mixed▶
McKesson reported fiscal Q4 2026 results showing consolidated revenue of $96.3B (+6% YoY but ~5.3% below consensus), GAAP EPS of $13.71 (+$3) and adjusted EPS of $11.69 (+16% YoY, ~1.1% above consensus), pressured by price declines and lower GLP-1 distribution volumes. The board approved an additional $5.0B share buyback bringing total authorization to $7.7B as of April 2026, alongside a $2.25B accelerated share repurchase program. Brian Tyler became Board Chair effective May 1; Kenny Cheung joins as EVP/CFO May 29. Apollo Funds is investing $1.25B in convertible preferred for ~13% of McKesson's Medical-Surgical Solutions unit (valuing MMS at ~$13B). Analyst PT moves: UBS raised to $1,050 (May 8); Citi cut to $945 (May 14); analyst reiterated Buy May 15 citing biosimilar tailwinds. Bear case: revenue miss and ongoing GLP-1 distribution softness signal margin pressure if specialty growth slows.
May 15McKesson posted FY26 EPS of $39.11 and raised FY27 guidance to $43.80-$44.60 while announcing a $2.25B accelerated share repurchase on May 13.Mixed▶
McKesson reported FY26 Q4/full-year results May 13 with full-year revenue of $403.4B and adjusted EPS of $39.11 (+16% YoY). Management raised FY27 adjusted EPS guidance to $43.80-$44.60 and announced a $2.25B accelerated share repurchase program. Brian Tyler was elected Board Chair effective May 1, with Kenny Cheung joining as EVP and CFO May 29. McKesson also signed a deal with Apollo Funds for a $1.25B investment for ~13% minority interest in its Medical-Surgical Solutions business, valuing the unit at ~$13B as part of separation/IPO preparation. Multiple analysts adjusted PTs after Q1 results showed a revenue miss: Citi $945 (from $975), UBS $1,050 (from $1,000), Evercore ISI $850 (from $950), Baird $941 (from $1,010), Deutsche Bank $875 (from $973), JPMorgan $1,015 (from $1,107).
May 14McKesson reported FY26 Q4 EPS of $11.69 beating estimates but missed revenue, attended BofA Healthcare Conference May 12 as Brian Tyler became ChairMixed▶
McKesson reported on May 7 fiscal Q4 2026 results with revenue of $96.3 billion (up 6% YoY but missing analyst expectations by 5.5%) and adjusted EPS of $11.69 (up 16%, beating consensus by 1.1%). Full-year revenue reached $403.4 billion (+12%) with adjusted EPS of $39.11 (+18%). The company entered a $2.25 billion accelerated share repurchase and the board approved an additional $5.0 billion buyback authorization, bringing total authorized repurchases to $7.7 billion. Effective May 1, Brian Tyler became Board Chair and Dominic Caruso became Lead Independent Director, with long-time CFO Britt Vitalone retiring and Kenny Cheung taking the CFO role. McKesson participated in the BofA Securities 2026 Healthcare Conference on May 12, and UBS raised its price target to $1,050. The bear case is the revenue miss reflecting weakness in distribution growth plus leadership transition risk during CFO handover.
May 13McKesson signed agreement with Apollo Funds for ~13% minority stake in Medical-Surgical Solutions unit and authorized additional $5B share buyback alongside FY26 Q4 earnings.Mixed▶
McKesson reported fiscal Q4 2026 revenue of $96.3B (+6% YoY) and adjusted EPS of $11.69 (+16%), but revenue missed analyst estimates by ~5.5%. The company issued FY27 adjusted EPS guidance of $43.80-$44.60, implying 12-14% growth. Apollo Global will acquire approximately 13% minority interest in the Medical-Surgical Solutions segment in a $1.25B deal, signaling portfolio optimization. The board authorized an additional $5.0B share repurchase, bringing total authorization to $7.7B. Brian Tyler was elected Chair effective May 1, and Kenny Cheung joins as CFO May 29.
May 12McKesson posts FY26 Q4 revenue of $96.3B (up 6%) and adjusted EPS of $11.69 (up 16%); Apollo to take 13% stake in Med-Surg unit at $13B valuation.Mixed▶
McKesson reported fiscal Q4 2026 results on May 7, 2026 with consolidated revenues of $96.3 billion (up 6% YoY) and adjusted EPS of $11.69 (up 16% YoY, beating consensus by 1.1%). FY27 guidance calls for 7% sales growth and 14% EPS growth. The Board approved an additional $5.0B share repurchase authorization, bringing total to $7.7B, after completing $2.7B repurchases in Q4. Apollo Funds will invest $1.25B in convertible preferred equity for ~13% minority stake in McKesson Medical-Surgical Solutions, valuing the unit at ~$13B. Brian Tyler became Chair effective May 1, with Kenny Cheung joining as EVP & CFO May 29. UBS raised PT to $1,050; multiple analysts cut targets including Evercore ($850), BofA ($900), Deutsche Bank ($875), and JPMorgan ($1,015).
Sector Peers
| Company | Price | Day | 1M | Fwd P/E | Beta | Mkt Cap |
|---|---|---|---|---|---|---|
| MCKMCKESSON | $750.08 | -3.81% | -0.5% | 14.9x | 0.32 | $87.9B |
| CORCENCORA | $271.88 | -1.88% | +2.7% | 13.7x | 0.59 | $52.9B |
| CAHCARDINAL | $222.34 | -1.74% | +11.3% | 18.5x | 0.53 | $51.9B |
| HSICHENRY | $79.92 | -0.06% | +9.1% | 13.5x | 0.82 | $9.1B |
| LLYELI | $1,099.89 | -1.09% | +7.8% | 24.7x | 0.52 | $979.6B |
Key Fundamentals
RSI (14-Day)
52-Week Range
Moving Averages
Price below 200d MA — bearish structure.